Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/680"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_type | |
| ?:Evidence_value |
"3.82"
|
| ?:content |
"NOTE: AUC_I/AUC in the DIKB knowledge-base is from the 6 participants classified as homozygous EMs.
route of administration: oral
study duration: six days
population: 18 healthy volunteers (9 male, 9 female); All Japanese
tested for known CYP450 polymorphisms?
Yes -- CYP2C19 - 6 homozygous EMs, 6 heterozygous EMs, 6 homozygous PMs
ages: mean 25 years (+/- 3.8)
description:
Eighteen healthy Japanese volunteers (9 men and 9
women) who were H. pylori-negative were enrolled in this study. Their mean age was 25.1 +/- 3.8 years and mean body weight was 56.6 +/- 13.3 kg. The mutated alleles for CYP2C19, CYP2C19*3(*3), and CYP2C19*2(*2) had been identified using polymerase chain reaction-restriction fragment length polymorphism methods of De Morais et al, before this study. The CYP2C19 genotype analyses revealed 5 different patterns as follows: *1/*1 in 6, *1/*2 in 3, *1/*3 in 3, *2/*2 in 5, and *2/*3 in 1. These were divided into 3 groups, homozygous EMs (*1/*1, n = 6), heterozygous EMs (*1/*2 and *1/*3, n = 6), and PMs (*2/*2 and *2/*3, n = 6).
A randomized double-blind placebo-controlled
crossover study design in 3 phases was conducted at
intervals of 2 weeks. Fluvoxamine (25 mg) as a capsule containing the equivalent of a tablet (Luvox, Fujisawa Pharmaceutical Co, Ltd, Osaka, Japan), or matched placebo was given orally twice a day (9 AM, 9 PM) for 6 days. On day 6, they took a single oral 60-mg
dose of lansoprazole (Takepron, Takeda Pharmaceutical
Co, Ltd, Osaka, Japan) with 25 mg dose of fluvoxamine, or placebo after overnight fasting (9 AM).
Fluvoxamine pretreatment significantly increased AUC_0-24 of lansoprazole by 3.8-fold in homozygous EMs (P<0.01) and 2.5-fold in heterozygous EMs (P<0.05), and prolonged elimination half-life by 3.0-fold in homozygous EMs (P<0.01) and by 1.7-fold in heterozygous EMs (P<0.05), respectively. There were no differences in AUC_0-24 during fluvoxamine treatment among CYP2C19 genotypes."
|
| dc:creator | |
| dc:date |
"08/10/2010 14:43:34"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ fluvoxamine_increases_auc_lansoprazole, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1902 }